News Quantified

AGIO – agios pharmaceuticals, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

MOMA Therapeutics Appoints Susan Pandya, M.D., to Board of Directors and Expands Management Team [Yahoo! Finance]

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer

Agios to Present at Upcoming Investor Conferences

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $58.00 price target on the stock.

Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025

-6.9%

MISS

-3.3%

MISS

3.2%

BEAT

H.C. WAINWRIGHT

H.C. WAINWRIGHT

Form 4 AGIOS PHARMACEUTICALS, For: Mar 05 Filed by: Viswanadhan Krishnan

Form 3 AGIOS PHARMACEUTICALS, For: Mar 05 Filed by: Viswanadhan Krishnan

Form S-8 AGIOS PHARMACEUTICALS,

Form 4 AGIOS PHARMACEUTICALS, For: Mar 01 Filed by: Burns James William

Form 4 AGIOS PHARMACEUTICALS, For: Mar 01 Filed by: Jones Cecilia

Top News Gainers

1/13 Form 8-K AGIOS PHARMACEUTICALS, For: Jan 13 8.7%

11/5 Agios Pharmaceuticals Inc (NASDAQ: AGIO) had its price target lowered by analysts at Citigroup Inc from $80.00 to $64.00. They now have a "buy" rating on the stock. 7.9%

9/10 Agios to Present Data From the Phase 3 ClarIDHy Study of TIBSOVO® in Previously Treated IDH1 Mutant Cholangiocarcinoma in Presidential Symposium at ESMO 6.2%

10/2 Agios Pharmaceuticals Inc (NASDAQ: AGIO) had its "buy" rating re-affirmed by analysts at Cowen Inc. 5.6%

12/9 Form 8-K AGIOS PHARMACEUTICALS, For: Dec 08 5.4%

6/14 Form 4 AGIOS PHARMACEUTICALS For: Jun 12 Filed by: MARAGANORE JOHN 5.4%

2/13 Q4/2019 12/31/2019 EPS -1.600 ZacksConsensus -1.780 ActVsEst 0.180 - Beat 5.3%

7/30 Agios Pharmaceuticals Inc (NASDAQ: AGIO) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 5.1%

5/15 Agios Announces the Randomized Phase 3 ClarIDHy Trial of TIBSOVO® (ivosidenib) Achieved its Primary Endpoint in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients 5.0%

4/16 Form DEF 14A AGIOS PHARMACEUTICALS, For: May 28 5.0%

Top News Decliners

5/1 Agios Pharmaceuticals Inc (NASDAQ: AGIO) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. They now have a $72.00 price target on the stock. -13.0%

8/1 Form 10-Q AGIOS PHARMACEUTICALS, For: Jun 30 -11.2%

12/9 Agios Presents Translational Data to Further Characterize the Role of TIBSOVO® (ivosidenib) Treatment in IDH1 Mutant Acute Myeloid Leukemia (AML) -8.8%

5/16 Agios Pharmaceuticals Inc (NASDAQ: AGIO) had its "buy" rating re-affirmed by analysts at Cowen Inc. -7.9%

4/30 Agios Pharmaceuticals Inc (NASDAQ: AGIO) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -6.6%

1/13 TIO Bioventures Launches Treadwell Therapeutics, Seeded With $27m to Develop First-in-Class Oral Medicines Against Novel Targets -6.2%

10/28 Form 8-K AGIOS PHARMACEUTICALS, For: Oct 27 -6.2%

9/30 Data from Agios’ Phase 3 ClarIDHy Trial of TIBSOVO® Demonstrates Significant Improvement in Progression Free Survival (PFS) Compared to Placebo in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients -6.2%

2/24 Form 4 AGIOS PHARMACEUTICALS, For: Feb 20 Filed by: Alenson Carman -6.0%

2/14 Agios Pharmaceuticals Inc (NASDAQ: AGIO) had its "hold" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. -5.1%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day